HRS 5580
Alternative Names: HRS-5580; Rolapitant PRODRUG - Fujian Shengdi PharmaceuticalLatest Information Update: 09 Sep 2026
At a glance
- Originator Fujian Shengdi Pharmaceutical
- Class Antiemetics
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Postoperative nausea and vomiting
Most Recent Events
- 06 Aug 2026 Phase-II clinical trials in Postoperative nausea and vomiting (Prevention, Combination therapy) in China (Parenteral) (NCT07709897)
- 17 Jul 2026 Fujian Shengdi Pharmaceutical plans a phase II trial for Postoperative nausea and vomiting (Prevention, Combination therapy) in China (Parenteral, Injection) (NCT07709897)
- 29 Oct 2024 Fujian Shengdi Pharmaceutical completes a phase II trial in Postoperative nausea and vomiting (Prevention) in China (Parenteral) (NCT06475846)